322 related articles for article (PubMed ID: 29030741)
1. The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope.
Groisberg R; Roszik J; Conley A; Patel SR; Subbiah V
Curr Oncol Rep; 2017 Oct; 19(12):78. PubMed ID: 29030741
[TBL] [Abstract][Full Text] [Related]
2. Profiling of potential driver mutations in sarcomas by targeted next generation sequencing.
Andersson C; Fagman H; Hansson M; Enlund F
Cancer Genet; 2016 Apr; 209(4):154-60. PubMed ID: 26987750
[TBL] [Abstract][Full Text] [Related]
3. Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics.
Jour G; Scarborough JD; Jones RL; Loggers E; Pollack SM; Pritchard CC; Hoch BL
Hum Pathol; 2014 Aug; 45(8):1563-71. PubMed ID: 24908143
[TBL] [Abstract][Full Text] [Related]
4. Next-Generation Sequencing for Patients with Sarcoma: A Single Center Experience.
Cote GM; He J; Choy E
Oncologist; 2018 Feb; 23(2):234-242. PubMed ID: 28860410
[TBL] [Abstract][Full Text] [Related]
5. Targeted next-generation sequencing of CIC-DUX4 soft tissue sarcomas demonstrates low mutational burden and recurrent chromosome 1p loss.
Lazo de la Vega L; Hovelson DH; Cani AK; Liu CJ; McHugh JB; Lucas DR; Thomas DG; Patel RM; Tomlins SA
Hum Pathol; 2016 Dec; 58():161-170. PubMed ID: 27664537
[TBL] [Abstract][Full Text] [Related]
6. Role of Next-Generation Sequencing as a Diagnostic Tool for the Evaluation of Bone and Soft-Tissue Tumors.
Szurian K; Kashofer K; Liegl-Atzwanger B
Pathobiology; 2017; 84(6):323-338. PubMed ID: 28817827
[TBL] [Abstract][Full Text] [Related]
7. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
[TBL] [Abstract][Full Text] [Related]
8. The clinical utility of next-generation sequencing for bone and soft tissue sarcoma.
Gusho CA; Weiss MC; Lee L; Gitelis S; Blank AT; Wang D; Batus M
Acta Oncol; 2022 Jan; 61(1):38-44. PubMed ID: 34686105
[No Abstract] [Full Text] [Related]
9. Next-generation sequencing for the management of sarcomas with no known driver mutations.
Vyse S; Thway K; Huang PH; Jones RL
Curr Opin Oncol; 2021 Jul; 33(4):315-322. PubMed ID: 33927108
[TBL] [Abstract][Full Text] [Related]
10. Next generation sequencing in a cohort of patients with rare sarcoma histotypes: A single institution experience.
Tirrò E; Martorana F; Micale G; Inzerilli N; Carciotto R; Romano C; Longhitano C; Motta G; Lanzafame K; Stella S; Massimino M; Vitale SR; Salvatorelli L; Magro G; Manzella L; Vigneri P
Pathol Res Pract; 2022 Apr; 232():153820. PubMed ID: 35240549
[TBL] [Abstract][Full Text] [Related]
11. Molecular profiling of sarcomas: new vistas for precision medicine.
Al-Zaid T; Wang WL; Somaiah N; Lazar AJ
Virchows Arch; 2017 Aug; 471(2):243-255. PubMed ID: 28664413
[TBL] [Abstract][Full Text] [Related]
12. Is There Value in Molecular Profiling of Soft-Tissue Sarcoma?
Italiano A
Curr Treat Options Oncol; 2018 Dec; 19(12):78. PubMed ID: 30523434
[TBL] [Abstract][Full Text] [Related]
13. Genomic Profiling and Clinical Outcomes of Targeted Therapies in Adult Patients with Soft Tissue Sarcomas.
Kokkali S; Georgaki E; Mandrakis G; Valverde C; Theocharis S
Cells; 2023 Nov; 12(22):. PubMed ID: 37998367
[TBL] [Abstract][Full Text] [Related]
14. [Molecular pathology of soft tissue tumors: Contribution to diagnosis and therapy prediction].
Schmitz K; Schildhaus HU
Pathologe; 2015 Mar; 36(2):126-36. PubMed ID: 25822596
[TBL] [Abstract][Full Text] [Related]
15. Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma.
Lewin J; Garg S; Lau BY; Dickson BC; Traub F; Gokgoz N; Griffin AM; Ferguson PC; Andrulis IL; Sim HW; Kamel-Reid S; Stockley TL; Siu LL; Wunder JS; Razak ARA
Int J Cancer; 2018 Jan; 142(1):57-65. PubMed ID: 28891048
[TBL] [Abstract][Full Text] [Related]
16. Pathogenic and Targetable Genetic Alterations in Resected Recurrent Undifferentiated Pleomorphic Sarcomas Identified by Targeted Next-generation Sequencing.
Zheng B; Qu Y; Wang J; Shi Y; Yan W
Cancer Genomics Proteomics; 2019; 16(3):221-228. PubMed ID: 31018952
[TBL] [Abstract][Full Text] [Related]
17. What Would Next Generation Sequencing Bring to the Diagnosis and Treatment of Sarcomas? A Series of 20 Cases, a Single Institution's Experience.
Kulaç İ; Bulutay P; Meriçöz ÇA
Turk Patoloji Derg; 2021; 37(3):226-232. PubMed ID: 34514574
[TBL] [Abstract][Full Text] [Related]
18. Current updates in sarcoma biomarker discovery: emphasis on next-generation sequencing-based methods.
Patton A; Dermawan JK
Pathology; 2024 Mar; 56(2):274-282. PubMed ID: 38185613
[TBL] [Abstract][Full Text] [Related]
19. Massive parallel sequencing in sarcoma pathobiology: state of the art and perspectives.
Brenca M; Maestro R
Expert Rev Anticancer Ther; 2015; 15(12):1473-88. PubMed ID: 26536249
[TBL] [Abstract][Full Text] [Related]
20. Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial.
Italiano A; Dinart D; Soubeyran I; Bellera C; Espérou H; Delmas C; Mercier N; Albert S; Poignie L; Boland A; Bourdon A; Geneste D; Cavaille Q; Laizet Y; Khalifa E; Auzanneau C; Squiban B; Truffaux N; Olaso R; Gerber Z; Wallet C; Bénard A; Blay JY; Laurent-Puig P; Deleuze JF; Lucchesi C; Mathoulin-Pelissier S;
BMC Cancer; 2021 Nov; 21(1):1180. PubMed ID: 34740331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
